Physician Photo

Beverly M K Biller, MD

  • Phone: 617-726-7948
Department of Medicine
Clinical Interests
Pituitary disease
Cushing's syndrome
Growth hormone deficiency
Boston: Massachusetts General Hospital
Medical Education
MD, University of Oklahoma College of Medicine
Residency, Beth Israel Deaconess Medical Center
Fellowship, Massachusetts General Hospital
Board Certifications
Endocrinology, Diabetes & Metabolism, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Patient Age Group
Accepting New Patients


Beverly MK Biller, MD is an endocrinologist in the Massachusetts General Hospital (MGH) Neuroendocrine Clinical Center.  She is a faculty member in the Neuroendocrine Unit at MGH and a Professor of Medicine at Harvard Medical School.  Dr. Biller?s major clinical and research interests include the diagnosis and treatment of Cushing?s disease, prolactinomas, acromegaly, other pituitary tumors and sellar masses, and pituitary hormone deficiencies in adults. 


ResearchDr. Biller is a clinical investigator who focuses on pituitary disorders.  Major research interests include the diagnosis and treatment of Cushing?s disease, prolactinomas, acromegaly, other pituitary tumors and sellar masses as well as pituitary hormone deficiencies, including growth hormone deficiency in adults. 


Selected research publications from 2012-2013

van der Lely et al Long-Term Safety of Pegvisomant in Patients with Acromegaly...J Clin Endocrinol Metab. 2012 May; 97(5):1589

Fleseriu et al Mifepristone, a glucocorticoid receptor antagonist.... J Clin Endocrinol Metab. 2012 Jun;97(6):2039

Colao et al  A 12-month phase III study of pasireotide in Cushing?s disease.  N Engl J Med. 2012; 366:914

Biller et al 12-Month effects of once-weekly sustained-release growth hormone treatment... Pituitary. 2012 Aug 23

Bertagna  et al  LCI699, a potent 11?-hydroxylase inhibitor, normalizes urinary cortisol ... J Clin Endocrinol Metab. 2013 Dec 10

Experimental drug reduces cortisol levels, improves symptoms in Cushing's disease

A new investigational drug significantly reduced urinary cortisol levels and improved symptoms of Cushing's disease in the largest clinical study of this endocrine disorder ever conducted.

Neuroendocrine Clinical Center
Zero Emerson Place
Suite 112
Boston, MA 02114-2217

Phone: 617-726-7948
Fax: 617-726-1241